311 related articles for article (PubMed ID: 38389413)
1. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer.
Jaradat SK; Ayoub NM; Al Sharie AH; Aldaod JM
Technol Cancer Res Treat; 2024; 23():15330338241234780. PubMed ID: 38389413
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Nair A; Chung HC; Sun T; Tyagi S; Dobrolecki LE; Dominguez-Vidana R; Kurley SJ; Orellana M; Renwick A; Henke DM; Katsonis P; Schmitt E; Chan DW; Li H; Mao S; Petrovic I; Creighton CJ; Gutierrez C; Dubrulle J; Stossi F; Tyner JW; Lichtarge O; Lin CY; Zhang B; Scott KL; Hilsenbeck SG; Sun J; Yu X; Osborne CK; Schiff R; Christensen JG; Shields DJ; Rimawi MF; Ellis MJ; Shaw CA; Lewis MT; Westbrook TF
Nat Med; 2018 May; 24(4):505-511. PubMed ID: 29578538
[TBL] [Abstract][Full Text] [Related]
3. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
[TBL] [Abstract][Full Text] [Related]
4. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
6. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
7. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
8. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
9. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
11. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
Mehlich D; Marusiak AA
Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
[TBL] [Abstract][Full Text] [Related]
12. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of PTK7 Reduces the Oncogenic Potential of Breast Cancer Cells by Impeding Receptor Tyrosine Kinase Signaling.
Shin WS; Oh SW; Park HN; Kim JH; Lee ST
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569547
[TBL] [Abstract][Full Text] [Related]
14. G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.
Blake A; Dragan M; Tirona RG; Hardy DB; Brackstone M; Tuck AB; Babwah AV; Bhattacharya M
Sci Rep; 2017 Apr; 7():46525. PubMed ID: 28422142
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer.
Ozyurt R; Ozpolat B
Mol Cancer Ther; 2023 Jul; 22(7):818-832. PubMed ID: 37028809
[TBL] [Abstract][Full Text] [Related]
16. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
17. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.
Lanning NJ; Castle JP; Singh SJ; Leon AN; Tovar EA; Sanghera A; MacKeigan JP; Filipp FV; Graveel CR
Cancer Metab; 2017; 5():6. PubMed ID: 28852500
[TBL] [Abstract][Full Text] [Related]
18. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
19. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
Cao W; Li J; Hao Q; Vadgama JV; Wu Y
Breast Cancer Res; 2019 Feb; 21(1):29. PubMed ID: 30791936
[TBL] [Abstract][Full Text] [Related]
20. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
